Forward-looking statements

This website contains forward-looking statements about ImmuVia, Inc. (“ImmuVia,” “we,” or “our”) and its programs. Forward-looking statements are statements that are not historical facts and often can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “will,” “could,” “potential,” “designed to,” and similar expressions, although not all forward-looking statements contain these words.

Examples of forward-looking statements

Forward-looking statements on this website include, among others, statements regarding:

• the nature, progress, and anticipated timing of our IND-enabling activities and regulatory submissions;
• the design, conduct, expected initiation, and timing of our planned preclinical studies and future clinical trials;
• the therapeutic potential, mechanism of action, and possible efficacy and safety of IMV-M™ and our Cancerlysin™ platform;
• our manufacturing plans and our ability to develop and supply product candidates;
• the scope, strength, and enforceability of our intellectual property;
• our business strategy, including potential collaborations, partnering, and financing activities, and our future capital requirements.

Risks and uncertainties

These statements are based on management’s current expectations, estimates, and assumptions and are subject to substantial risks and uncertainties, many of which are outside our control. Drug development is a lengthy, expensive, and inherently uncertain process. Actual results and the timing of events could differ materially from those expressed or implied by our forward-looking statements as a result of various factors, including, among others:

• preclinical and other early results may not be predictive of future results, and promising results in early studies may not be replicated in later preclinical or clinical studies;
• our planned preclinical studies and clinical trials may be delayed, may not begin or be completed on the anticipated timeline, or may not be conducted at all;
• the U.S. Food and Drug Administration and other regulatory authorities may not agree with our plans, proposed study designs, or interpretations of data, and may require additional studies or impose other requirements;
• our product candidates may fail to demonstrate adequate safety or efficacy, may produce undesirable side effects, and may never receive regulatory approval or achieve commercial success;
• we rely, and expect to continue to rely, on third parties such as contract research and manufacturing organizations and potential collaborators, and their performance is not fully within our control;
• we will require substantial additional capital to advance our programs, and such capital may not be available on acceptable terms, or at all;
• we face significant competition, and competitors may develop products that are safer, more effective, or commercialized more quickly than ours;
• we may be unable to obtain, maintain, defend, or enforce intellectual property protection for our technology and product candidates, or we may infringe the rights of others.

No duty to update

Any forward-looking statement on this website speaks only as of the date on which it was made. Except as required by law, ImmuVia undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. You should not place undue reliance on these statements.

Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.